IL6 and heart failure: Furthermore, these high‐risk individuals may be targets for new treatments, which is particularly intriguing in light of contemporary phase three trials of anti‐IL‐6 drugs for the treatment of major complications of diabetes, such as atherosclerotic diseases (ClinicalTrials.gov ID NCT05021835) and heart failure (ClinicalTrials.gov ID NCT05636176), and a Phase II trial of anti‐suPAR treatment for treating kidney diseases (ClinicalTrials.gov ID NCT06466135).